These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11409425)

  • 21. Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria.
    Hemmen TM; Rapp KS; Emond JA; Raman R; Lyden PD
    J Stroke Cerebrovasc Dis; 2010; 19(4):290-3. PubMed ID: 20471855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eligibility determination for intravenous thrombolysis based on radiology interpretation report of the head CT scan in patients with acute ischemic stroke.
    Hassan AE; Majidi S; Janjua NA; Chaudhry SA; Tekle WG; Grigoryan M; Qureshi AI
    J Neuroimaging; 2014; 24(4):349-53. PubMed ID: 24015702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Plasma D-Dimer Indicates Unfavorable Outcome of Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis.
    Hsu PJ; Chen CH; Yeh SJ; Tsai LK; Tang SC; Jeng JS
    Cerebrovasc Dis; 2016; 42(1-2):117-21. PubMed ID: 27088493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
    Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
    Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?
    Hassan AE; Chaudhry SA; Jani V; Grigoryan M; Khan AA; Adil MM; Qureshi AI
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):545-9. PubMed ID: 23453555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Interventional Management of Stroke (IMS) II Study.
    IMS II Trial Investigators
    Stroke; 2007 Jul; 38(7):2127-35. PubMed ID: 17525387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice.
    Chiu D; Krieger D; Villar-Cordova C; Kasner SE; Morgenstern LB; Bratina PL; Yatsu FM; Grotta JC
    Stroke; 1998 Jan; 29(1):18-22. PubMed ID: 9445322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels.
    Saidi S; Slamia LB; Ammou SB; Mahjoub T; Almawi WY
    J Stroke Cerebrovasc Dis; 2007; 16(4):160-6. PubMed ID: 17689412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.
    Marler JR; Tilley BC; Lu M; Brott TG; Lyden PC; Grotta JC; Broderick JP; Levine SR; Frankel MP; Horowitz SH; Haley EC; Lewandowski CA; Kwiatkowski TP
    Neurology; 2000 Dec; 55(11):1649-55. PubMed ID: 11113218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan.
    Kobori S; Nakamura N; Uzawa H; Shichiri M
    Atherosclerosis; 1988 Jan; 69(1):81-8. PubMed ID: 3355609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials.
    Thomalla G; Schwark C; Sobesky J; Bluhmki E; Fiebach JB; Fiehler J; Zaro Weber O; Kucinski T; Juettler E; Ringleb PA; Zeumer H; Weiller C; Hacke W; Schellinger PD; Röther J;
    Stroke; 2006 Mar; 37(3):852-8. PubMed ID: 16439696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
    IMS Study Investigators
    Stroke; 2004 Apr; 35(4):904-11. PubMed ID: 15017018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1).
    Charidimou A; Pasi M; Fiorelli M; Shams S; von Kummer R; Pantoni L; Rost N
    Stroke; 2016 Sep; 47(9):2364-72. PubMed ID: 27491738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of intravenous recombinant tissue plasminogen activator for acute ischemic stroke in patients aged over 80 years.
    Mione G; Ducrocq X; Thilly N; Lacour JC; Vespignani H; Richard S
    Geriatr Gerontol Int; 2016 Jul; 16(7):843-9. PubMed ID: 26245693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.
    Lawson TR; Brown IE; Westerkam DL; Blackhurst DW; Sternberg S; Leacock R; Nathaniel TI
    Restor Neurol Neurosci; 2015; 33(3):301-8. PubMed ID: 25698111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.
    Clark WM; Albers GW; Madden KP; Hamilton S
    Stroke; 2000 Apr; 31(4):811-6. PubMed ID: 10753980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.
    Brown DL; Johnston KC; Wagner DP; Haley EC
    Stroke; 2004 Jan; 35(1):147-50. PubMed ID: 14657446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological disorders and Stroke Tissue Plasminogen Activator Stroke Trial.
    Saposnik G; Demchuk A; Tu JV; Johnston SC;
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):876-82. PubMed ID: 23102741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.